Curiox BioSystems
Financials
Valuation Metrics
Curiox BioSystems's Market Cap is ₩1.0T. At end of 2025 it was ₩2.0T. Ranked #309 of 2,419 in KR market (top 13%), #88 of 1,638 on KOSDAQ (top 5%), #34 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 15%) by Market Cap.
Investment Metrics(as of 2026-10-07)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 1.02T KRW | KR#309/2,419 Sec#34/231 |
| Revenue | 5.73B KRW | KR#2,329/2,419 Sec#189/231 |
| Net Income | -12.78B KRW | KR—/2,419 Sec—/231 |
| Total Assets | 53.33B KRW | KR#2,181/2,419 Sec#196/231 |
| Net Assets | 48.99B KRW | KR#1,918/2,419 Sec#160/231 |
| Employees | 23 | KR#2,238/2,419 Sec#210/231 |
| Value | ||
| P/B | 20.78x | KR#2,399/2,419 Sec#223/231 |
| P/S | 177.52x | KR#2,397/2,419 Sec#216/231 |
| FCF Yield | -1.10% | KR—/2,419 Sec—/231 |
| Profitability | ||
| ROE | -26.09% | KR#2,146/2,419 Sec#167/231 |
| ROA | -23.96% | KR#2,273/2,419 Sec#185/231 |
| Op. Margin | -227.43% | KR#2,336/2,419 Sec#187/231 |
| Revenue Growth | 49.92% | KR#209/2,419 Sec#29/231 |
| Financial Health | ||
| Debt Ratio | 8.87% | KR#118/2,419 Sec#25/231 |
| Total Debt | 0 KRW | KR—/2,419 Sec—/231 |
| FCF | -11.25B KRW | KR#1,744/2,419 Sec#156/231 |
| Cash | 10.50B KRW | KR#1,664/2,419 Sec#141/231 |
| Current Ratio | 5.24x | KR#266/2,419 Sec#49/231 |
| Performance | ||
| 1Y Return | -16.88% | KR#1,634/2,419 Sec#135/231 |
| 1M Return | 16.57% | KR#367/2,419 Sec#33/231 |
| From 52W High | -60.39% | KR#1,911/2,419 Sec#159/231 |
| 1Y MDD | -75.43% | KR#2,191/2,419 Sec#193/231 |
| Trading | ||
| Volume | 62,861 shares | KR#1,028/2,419 Sec#118/231 |
| Trading Value | 3.79B KRW | KR#432/2,419 Sec#56/231 |
| Foreign Own. | 7.03% | KR#635/2,419 Sec#56/231 |
| Per Share | ||
| EPS | -742 KRW | KR—/2,419 Sec—/231 |
| BPS | 2,844 KRW | KR#1,902/2,419 Sec#145/231 |
Company Info
Curiox Biosystems was established in 2018 to commercialize cell analysis process automation technology, developing a global sales network via subsidiaries in the United States, China, and Singapore. The company sells automated cell pre-processing equipment, plates, and accessories, featuring its unique Curiox C-FREE™ technology that significantly improves automation, data accuracy, and reproducibility in cell analysis. This non-centrifuge-based automated cell pre-processing product grants it a distinctive market position. Curiox Biosystems is headquartered in Geumcheon-gu, Seoul Metropolitan City.